Statin monotherapy does not enable most patients with established atherosclerotic cardiovascular disease (ASCVD) to achieve the 2025 ESC lipid targets.1 Inclisiran is reimbursed for use in primary care in England for patients with ASCVD and an LDL-C ≥2.6mmol/l.2 Despite its strong evidence base, favourable safety profile, and national reimbursement scheme, reluctance to initiate inclisiran persists among some UK healthcare professionals (HCPs).To identify barriers to inclisiran use among UK HCPsA cross-sectional lipid-based electronic survey was conducted between September and October 2025 on HCPs from the Primary Care Cardiovascular Society (UK) membership database. One of the questions explored barriers to using lipid-lowering therapies beyond statins.69 HCPs responded to the questionnaire: 28 (41%) were GPs (including GPs with a special interest in CVD or trainee GPs), 20 pharmacists, 16 nurses, and 5 other HCP types. 3 HCPs used statins alone – 2 citing the local medical committee (LMC) as a barrier to prescribing other medicines. Of the 40 who didn’t use inclisiran, several barriers were cited, including lack of outcome data (n=6, 15%), cost (n=7, 17.5%), unfamiliarity (n=12, 30%) and advice from the local medical committee (LMC, n=17, 43%).LMC advice, followed by unfamiliarity with inclisiran, appear to be the most influential barriers to its adoption in UK primary care.Targeted education and peer support may increase clinician familiarity, confidence and uptake of inclisiran. Given the substantial impact of LMC guidance on prescribing behaviour, careful consideration by influential organisations must be taken to avoid unintentionally limiting patient access to guideline-directed lipid-lowering therapies.